Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase 1B/2 Study to Evaluate the Safety and Efficacy of Tabelecleucel in Combination With Pembrolizumab in Subjects With Platinum-pretreated, Recurrent/Metastatic Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma

NCT03769467 is registered in ClinicalTrials.gov with Atara Biotherapeutics as lead sponsor.

NCT NCT03769467
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03769467 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase 1B/2 Study to Evaluate the Safety and Efficacy of Tabelecleucel in Combination With Pembrolizumab in Subjects With Platinum-pretreated, Recurrent/Metastatic Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma
Lead sponsor
Atara Biotherapeutics
Phase
Phase 1/2
Overall status
Terminated
Start date
February 19, 2019
Completion date
August 19, 2021
Enrollment
12 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

epstein-barr viraemia, epstein-barr virus infections, epstein-barr virus-associated nasopharyngeal carcinoma (ebv+ npc), nasopharyngeal carcinoma, nasopharyngeal neoplasms